OAM
ORMP icon

Oxford Asset Management’s Oramed Pharmaceuticals ORMP Stock Holding History

Oxford Asset Management’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-10,072
Closed -$25.9K – 415
2024
Q2 		$25.9K Buy
+10,072
New +$23.9K 0.03% 268
2018
Q1 		– Sell
-12,575
Closed -$116K – 1819
2017
Q4 		$116K Buy
+12,575
New +$120K ﹤0.01% 1514

Other funds holding ORMP

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $25B AUM 18.87% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Oxford Asset Management's ORMP Position: Q3 2024 in Review

Oxford Asset Management sold out of Oramed Pharmaceuticals (ORMP) in Q3 2024, closing a stake of 10,072 shares — an estimated $25.9K sold.

Oxford Asset Management first reported a position in ORMP in Q4 2017 and held it in 2 quarters. The position peaked at $116K in Q4 2017. 55 funds tracked by Wall St. Rank hold ORMP as of Q3 2024.

  • Oxford Asset Management reported no remaining Oramed Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Oxford Asset Management sold 10,072 Oramed Pharmaceuticals shares in Q3 2024, an estimated $25.9K.
  • Oxford Asset Management first reported a position in Oramed Pharmaceuticals in Q4 2017 and held it in 2 quarters.
  • Oxford Asset Management's Oramed Pharmaceuticals position peaked at $116K in Q4 2017.
  • 55 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q3 2024.

Based on Oxford Asset Management's 13F filing for Q3 2024, filed 14 Nov 2024.